These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 620476)

  • 1. Biological determinants of propranolol disposition in man.
    Kornhauser DM; Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1978 Feb; 23(2):165-74. PubMed ID: 620476
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing.
    Wells PG; Feely J; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1983 May; 33(5):603-8. PubMed ID: 6839632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis.
    Olanoff LS; Walle T; Cowart TD; Walle UK; Oexmann MJ; Conradi EC
    Clin Pharmacol Ther; 1986 Oct; 40(4):408-14. PubMed ID: 3757404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct measurement of propranolol bioavailability during accumulation to steady-state.
    Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG
    Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.
    Evans GH; Shand DG
    Clin Pharmacol Ther; 1973; 14(4):487-93. PubMed ID: 4723255
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose-dependent disposition of oral propranolol in normal subjects.
    Mackichan JJ; Pyszczynski DR; Jusko WJ
    Biopharm Drug Dispos; 1980; 1(4):159-66. PubMed ID: 7448344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic clearance of propranolol in dogs.
    Breckenridge A; Buranapong P; Dollery CT; George CF; Macerlean D; Orme ML
    Br J Pharmacol; 1973 Jun; 48(2):336P-337P. PubMed ID: 4733741
    [No Abstract]   [Full Text] [Related]  

  • 13. The disposition of propranolol. I. Elimination during oral absorption in man.
    Shand DG; Rangno RE
    Pharmacology; 1972; 7(3):159-68. PubMed ID: 5054586
    [No Abstract]   [Full Text] [Related]  

  • 14. Propranolol disposition in chronic liver disease: a physiological approach.
    Branch RA; Shand DG
    Clin Pharmacokinet; 1976; 1(4):264-79. PubMed ID: 797499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.
    Bai SA; Walle UK; Walle T
    J Pharmacokinet Biopharm; 1985 Jun; 13(3):229-41. PubMed ID: 4087163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of age and cigarette smoking on propranolol disposition.
    Vestal RE; Wood AJ; Branch RA; Shand DG; Wilkinson GR
    Clin Pharmacol Ther; 1979 Jul; 26(1):8-15. PubMed ID: 445965
    [No Abstract]   [Full Text] [Related]  

  • 17. Partial metabolic clearances as determinants of the oral bioavailability of propranolol.
    Walle T; Walle UK; Olanoff LS; Conradi EC
    Br J Clin Pharmacol; 1986 Sep; 22(3):317-23. PubMed ID: 3768243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of liver blood flow and propranolol metabolism by cimetidine.
    Feely J; Wilkinson GR; Wood AJ
    N Engl J Med; 1981 Mar; 304(12):692-5. PubMed ID: 7464861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.
    Evans GH; Shand DG
    Clin Pharmacol Ther; 1973; 14(4):494-500. PubMed ID: 4723256
    [No Abstract]   [Full Text] [Related]  

  • 20. The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol.
    Nies AS; Evans GH; Shand DG
    J Pharmacol Exp Ther; 1973 Mar; 184(3):716-20. PubMed ID: 4631471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.